VisitBest guide

Top 17 Pharmaceutical Companies in India (2026)

Profile the 17 leading pharmaceutical companies in India — Sun Pharma, Cipla, Dr Reddy’s, Divi’s, Biocon and more — each with its headquarters, founding…

In this guide
Best pharma companies in India — compiled cover of official company logos
Image used inside the guide.
Advertisement

India supplies a large share of the world's generic medicines, and its biggest drugmakers now combine that manufacturing strength with research, biosimilars and branded speciality products. This guide profiles 17 of the country's leading pharmaceutical companies, from Mumbai and Hyderabad to Ahmedabad and Bengaluru.

Each profile is based on fresh research carried out in November 2026. It covers what the company is known for, where it is based and the developments reported during 2025 and 2026, such as launches, approvals and acquisitions.

Quick answer

If you only have a minute, these are the names that define Indian pharma today:

  • Sun Pharmaceutical Industries — described by the company as India's largest pharmaceutical company, with a growing global speciality business
  • Cipla — a household name in respiratory care, now also selling Eli Lilly's diabetes and obesity medicine tirzepatide under a second brand
  • Dr Reddy's Laboratories — a global generics major that has added consumer healthcare brands, including nicotine replacement therapy
  • Divi's Laboratories — the behind-the-scenes specialist that makes active ingredients and custom molecules for drugmakers worldwide
  • Biocon — India's biosimilars leader, built on insulin and complex biological medicines
  • Zydus Lifesciences and Lupin — large branded-formulation groups expanding into biosimilars and new therapy areas

The full list of 17 also includes Aurobindo Pharma, Torrent Pharmaceuticals, Mankind Pharma, Alkem Laboratories, Glenmark Pharmaceuticals, Laurus Labs, Abbott India, Ipca Laboratories, Ajanta Pharma and JB Chemicals and Pharmaceuticals.

The Indian pharmaceutical industry today

India is the world's third largest pharmaceutical producer by volume and its largest supplier of generic medicines. According to the India Brand Equity Foundation (IBEF), citing Bain and Company, the Indian market was worth about US$55 billion in 2025 and could reach US$120 to 130 billion by 2030.

Government figures tell a similar story of scale. The Economic Survey 2025-26, reported by the Press Information Bureau, put sector turnover at ₹4.72 lakh crore in 2024-25, with exports of US$30.5 billion to 191 countries.

  • India supplies roughly 20 per cent of the world's generic medicines by volume, according to IBEF
  • The country ranks third globally in production volume and eleventh in value, per the Economic Survey 2025-26
  • More than 3,000 companies and over 10,500 manufacturing facilities operate in the sector
  • Indian makers supply an estimated 55 to 60 per cent of UNICEF's vaccine requirements
  • About half of export value goes to regulated markets such as the United States and Europe
  • Growth areas in 2025-26 include GLP-1 diabetes and obesity medicines, biosimilars and contract manufacturing for global firms

The 17 companies at a glance

CompanyHeadquartersBest known for
Sun Pharmaceutical IndustriesMumbaiSpeciality medicines and generics
CiplaMumbaiRespiratory care and affordable medicines
Dr Reddy's LaboratoriesHyderabadGenerics and branded formulations worldwide
Divi's LaboratoriesHyderabadAPIs and custom synthesis for global drugmakers
Zydus LifesciencesAhmedabadBranded formulations, vaccines and biosimilars
LupinMumbaiRespiratory and cardiovascular medicines
Aurobindo PharmaHyderabadGeneric formulations and APIs at global scale
Torrent PharmaceuticalsAhmedabadChronic therapy branded formulations
Mankind PharmaNew DelhiAffordable branded formulations and consumer healthcare
Alkem LaboratoriesMumbaiAnti-infectives and domestic branded generics
BioconBengaluruBiosimilars and insulin
Glenmark PharmaceuticalsMumbaiRespiratory, dermatology and novel drug research
Laurus LabsHyderabadAntiretroviral APIs and CDMO services
Abbott IndiaMumbaiBranded generics such as Thyronorm and Duphaston
Ipca LaboratoriesMumbaiAntimalarials, pain and rheumatology medicines
Ajanta PharmaMumbaiSpeciality branded generics, led by ophthalmology
JB Chemicals and PharmaceuticalsMumbaiCardiac and gastro brands such as Cilacar and Rantac

Company profiles

The profiles follow one format: a short summary, then the key facts. The order is an editorial selection, not a revenue league table, because reliable rankings differ by measure and change every quarter.

1. Sun Pharmaceutical Industries

Sun Pharma is described by the company as the largest pharmaceutical company in India. Founded in 1983 by Dilip Shanghvi, it has grown from a small formulations business into a global group selling generics and speciality medicines, with particular strength in dermatology, ophthalmology and onco-dermatology.

Its recent deals show where it is heading. In May 2025 it completed the acquisition of Checkpoint Therapeutics in the United States, adding the cancer immunotherapy UNLOXCYT. In April 2026 it agreed to acquire Organon, the women's health and biosimilars company, in a deal valuing it at about US$11.75 billion, expected to close in early 2027.

  • Headquarters: Mumbai, Maharashtra
  • Founded: 1983, by Dilip Shanghvi
  • Focus: speciality medicines, generics and consumer healthcare
  • Recent move: Checkpoint Therapeutics acquisition completed in May 2025
  • Announced in April 2026: agreement to acquire Organon for an enterprise value of about US$11.75 billion

2. Cipla

Cipla is one of India's best known drugmakers, built on affordable medicines for respiratory illness and HIV. Founded in 1935 and based in Mumbai, it sells inhalers, tablets and other formulations across India and many export markets.

Its biggest recent headline is in diabetes and obesity care. In October 2025 Cipla signed a marketing and distribution agreement with Eli Lilly for a second brand of tirzepatide in India, named Yurpeak, which it launched in December 2025. Lilly manufactures and supplies the medicine, and it is priced in line with Lilly's own brand.

  • Headquarters: Mumbai, Maharashtra
  • Founded: 1935
  • Focus: respiratory care, HIV medicines and chronic therapies
  • Recent move: launched Yurpeak, a second brand of Eli Lilly's tirzepatide, in December 2025

3. Dr Reddy's Laboratories

Dr Reddy's, founded in Hyderabad in 1984, is a global generics company with large businesses in India, North America, Europe and emerging markets. It sells branded formulations at home and a wide range of generic medicines abroad.

In September 2024 it completed the purchase of Haleon's nicotine replacement therapy portfolio outside the United States for £500 million, adding brands such as Nicotinell. The company reported record revenues for 2024-25, with sales up 17 per cent, and has positioned consumer healthcare as a new growth area alongside its generics base.

  • Headquarters: Hyderabad, Telangana
  • Founded: 1984
  • Focus: generics, branded formulations and consumer healthcare
  • Recent move: acquired Haleon's nicotine replacement portfolio outside the US in September 2024 for £500 million

4. Divi's Laboratories

Divi's Laboratories does not sell medicines under its own brand to patients. Founded in Hyderabad in 1990, it manufactures active pharmaceutical ingredients (APIs) and makes custom molecules for other drug companies, a business known as custom synthesis.

That model keeps it central to global supply chains. Brokerage research in 2026 put custom synthesis at just over half of its revenue. In May 2025 the company announced a long term supply agreement backed by customer funded capacity expansion, and it is investing in peptide manufacturing, including capacity aimed at GLP-1 medicines.

  • Headquarters: Hyderabad, Telangana
  • Founded: 1990
  • Focus: APIs and custom synthesis for global pharmaceutical companies
  • Recent move: long term supply agreement announced in May 2025, plus new peptide capacity

5. Zydus Lifesciences

Zydus Lifesciences, based in Ahmedabad, traces its roots to Cadila, founded in 1952. The group spans branded formulations, vaccines, wellness products and a fast growing biosimilars business.

It has been prominent in the GLP-1 wave. When the semaglutide patent expired in India in March 2026, Zydus launched its own generic versions under brands including Semaglyn, supported by co-marketing arrangements involving Lupin and Torrent. In February 2026 it launched Anyra, described as India's first indigenous biosimilar of the eye medicine aflibercept.

  • Headquarters: Ahmedabad, Gujarat
  • Roots: Cadila, founded in 1952
  • Focus: formulations, vaccines, wellness and biosimilars
  • Recent moves: generic semaglutide launched in March 2026; Anyra aflibercept biosimilar launched in February 2026

6. Lupin

Lupin was founded in Mumbai in 1968 by Desh Bandhu Gupta and is now a multinational company with a large presence in the United States, Japan and other markets. Respiratory medicine is its largest therapy area, alongside cardiovascular, diabetes and other chronic treatments.

In September 2025 Lupin agreed to acquire VISUfarma, a European ophthalmology company, at an enterprise value of €190 million, through its Dutch subsidiary. It also announced a US$250 million investment in a new respiratory manufacturing facility at Coral Springs, Florida, in October 2025.

  • Headquarters: Mumbai, Maharashtra
  • Founded: 1968, by Desh Bandhu Gupta
  • Focus: respiratory, cardiovascular and other chronic therapies; complex generics
  • Recent moves: VISUfarma acquisition agreed in September 2025; US$250 million Florida respiratory plant announced

7. Aurobindo Pharma

Aurobindo Pharma, founded in Hyderabad in 1986, is one of India's most export oriented drugmakers, selling generic formulations and APIs in more than 150 countries. The United States and Europe are its biggest markets.

The group now works through focused subsidiaries: Eugia for injectables and speciality products, CuraTeQ for biosimilars and Apitoria for APIs. During 2025 CuraTeQ won European and UK approvals for biosimilars including trastuzumab and bevacizumab products, as Aurobindo shifts part of its portfolio towards complex medicines.

  • Headquarters: Hyderabad, Telangana
  • Founded: 1986
  • Focus: generic formulations, APIs, injectables and biosimilars
  • Recent move: European and UK biosimilar approvals for its CuraTeQ unit during 2025

8. Torrent Pharmaceuticals

Torrent Pharmaceuticals is the flagship of the Ahmedabad based Torrent Group, whose origins go back to 1959. It is known for branded formulations in chronic therapies such as cardiac care, the central nervous system, diabetes and gastroenterology, with India as its anchor market.

In June 2025 Torrent agreed to acquire KKR's controlling stake of 46.39 per cent in JB Chemicals and Pharmaceuticals. Competition approval followed in October 2025, Torrent became JB's promoter in January 2026, and the merger of the two companies took effect in July 2026.

  • Headquarters: Ahmedabad, Gujarat
  • Origins: Torrent Group founded in 1959 by U. N. Mehta
  • Focus: chronic therapy branded formulations
  • Recent move: acquired control of JB Chemicals; merger effective July 2026

9. Mankind Pharma

Mankind Pharma, founded in 1991 and based in New Delhi, built its business on affordable branded formulations sold well beyond the big cities, alongside a consumer healthcare range. It is one of the largest India focused companies in this list.

Its largest deal to date closed in October 2024, when it completed the 100 per cent acquisition of Bharat Serums and Vaccines for ₹13,768 crore, adding strength in women's health and fertility treatments. In October 2025 the women's health branded generics portfolio of that business was transferred into Mankind itself.

  • Headquarters: New Delhi
  • Founded: 1991
  • Focus: affordable branded formulations and consumer healthcare
  • Recent move: completed the ₹13,768 crore acquisition of Bharat Serums and Vaccines in October 2024

10. Alkem Laboratories

Alkem Laboratories was founded in 1973 by Samprada Singh and is headquartered in Mumbai. It is a leader in acute therapies in India, especially anti-infectives, gastrointestinal medicines, pain management and nutrition products.

Its brands are among the most recognised at Indian pharmacies. Taxim became the first anti-infective brand in India to cross ₹100 crore in annual domestic sales, back in 2006, and Clavam remains one of the country's leading antibiotic combinations. Alkem has been ranked among the largest companies in the Indian domestic market, while also expanding its United States generics business.

  • Headquarters: Mumbai, Maharashtra
  • Founded: 1973, by Samprada Singh
  • Focus: anti-infectives, gastrointestinal, pain management and nutrition
  • Well known brands: Taxim and Clavam

11. Biocon

Biocon, founded in Bengaluru in 1978, is India's best known biotechnology company. Through Biocon Biologics it became a global biosimilars player, with ten commercialised biosimilars and a leading position in insulin, alongside a generics business.

In December 2025 Biocon announced the full integration of Biocon Biologics into the parent company, including buying out the residual stake held by Viatris for US$815 million, with completion expected by March 2026. Analysts cited by Moneycontrol place Biocon Biologics among the world's top five biosimilar companies by revenue.

  • Headquarters: Bengaluru, Karnataka
  • Founded: 1978
  • Focus: biosimilars, insulin and generics
  • Recent move: full integration of Biocon Biologics announced in December 2025

12. Glenmark Pharmaceuticals

Glenmark Pharmaceuticals was founded in Mumbai in 1977 by Gracias Saldanha. It sells branded and generic medicines across respiratory, dermatology and oncology, and is unusual among Indian peers for its investment in discovering entirely new drugs.

That research produced a landmark deal in July 2025, when its innovation arm, Ichnos Glenmark Innovation, licensed the experimental cancer drug ISB 2001 to AbbVie for global markets outside emerging economies. Glenmark received an upfront payment of US$700 million in September 2025, with up to US$1.225 billion more linked to milestones, plus royalties.

  • Headquarters: Mumbai, Maharashtra
  • Founded: 1977, by Gracias Saldanha
  • Focus: respiratory, dermatology, oncology and new drug discovery
  • Recent move: ISB 2001 licensed to AbbVie in July 2025; US$700 million upfront received

13. Laurus Labs

Laurus Labs was founded in Hyderabad in 2005 by Dr Satyanarayana Chava. It built its reputation supplying antiretroviral APIs used in HIV treatment worldwide, and has since added formulations and a fast growing contract development and manufacturing (CDMO) business.

Its results for the year to March 2026, announced in April 2026, showed revenue of ₹6,813 crore, up 23 per cent, with the CDMO division growing 36 per cent to ₹2,080 crore. The company operates 15 manufacturing sites.

  • Headquarters: Hyderabad, Telangana
  • Founded: 2005, by Dr Satyanarayana Chava
  • Focus: antiretroviral APIs, formulations and CDMO services
  • Recent results: revenue of ₹6,813 crore in the year to March 2026, up 23 per cent (company results)

14. Abbott India

Abbott India is the listed Indian arm of the global healthcare company Abbott Laboratories. The Indian company's own history goes back to 1944, and it focuses on branded generic medicines rather than the devices and nutrition businesses run by other Abbott units in India.

Its portfolio is built around long established brands prescribed across the country, including Thyronorm for thyroid care, Duphaston in women's health, and the gastroenterology brands Duphalac, Cremaffin and Digene. Its therapy areas include women's health, gastroenterology, metabolic disorders, the central nervous system and vaccines.

  • Headquarters: Mumbai, Maharashtra
  • Parent: Abbott Laboratories, United States
  • Focus: branded generics in women's health, gastroenterology and metabolic care
  • Well known brands: Thyronorm, Duphaston, Duphalac, Cremaffin and Digene

15. Ipca Laboratories

Ipca Laboratories, founded in Mumbai in 1949, is a vertically integrated company making both finished formulations and the APIs behind them. It markets more than 350 formulations and about 80 APIs, according to company descriptions.

Its strengths are pain management, rheumatology, cardiovascular medicines and antimalarials. Ipca is one of the world's largest suppliers of the antimalarial APIs hydroxychloroquine and chloroquine, as well as widely used ingredients such as atenolol and furosemide.

  • Headquarters: Mumbai, Maharashtra
  • Founded: 1949
  • Focus: pain, rheumatology, antimalarials and cardiovascular medicines
  • Known for: large scale API supply, including hydroxychloroquine

16. Ajanta Pharma

Ajanta Pharma, founded in 1973 and headquartered in Mumbai, is a speciality formulations company. It sells branded generics in India, Asia and Africa and generic medicines in the United States, with a ground presence in more than 30 countries.

The company is known for being first to market with many of its products, particularly in ophthalmology, dermatology, cardiology and pain management. In December 2025 it was reported to have in-licensed semaglutide from Biocon for 26 countries, with approvals expected from late 2026.

  • Headquarters: Mumbai, Maharashtra
  • Founded: 1973
  • Focus: speciality branded generics, led by ophthalmology
  • Recent move: semaglutide in-licensed from Biocon for 26 countries, reported in December 2025

17. JB Chemicals and Pharmaceuticals

JB Chemicals and Pharmaceuticals, usually shortened to JB Pharma, was founded in Mumbai in 1976 by the Mody family. It specialises in branded formulations, and describes itself as a leading player in hypertension treatment in India.

Its flagship brands include Cilacar and Nicardia for blood pressure, Rantac for acidity and Metrogyl for infections. KKR took a controlling stake in 2020. The company's next chapter is the Torrent acquisition: Torrent agreed to buy KKR's stake in June 2025, became promoter in January 2026, and the merger took effect in July 2026.

  • Headquarters: Mumbai, Maharashtra
  • Founded: 1976, by the Mody family
  • Focus: hypertension, gastroenterology and anti-infectives
  • Well known brands: Cilacar, Rantac, Metrogyl and Nicardia
  • Recent move: control passed to Torrent Pharmaceuticals during 2026

How this selection was made

The 17 companies were selected for their scale, their presence in the Indian market, their global footprint and their leadership in particular therapy areas or technologies such as biosimilars and APIs. Industry context uses published figures from IBEF and the Press Information Bureau.

Company facts were checked in November 2026 against company announcements, stock exchange filings and reputable business reporting. Where a ranking is mentioned, it is attributed to the source that published it. The order of profiles is editorial and is not a claim that one company is better than another.

What to verify before you rely on this list

  • Latest financial results: every listed company reports quarterly on BSE and NSE, and figures change fast
  • Deal status: announced acquisitions can complete late or on revised terms; the Sun Pharma and Organon deal, for example, was expected to close in early 2027 when announced
  • Regulatory standing: manufacturing plants are inspected by regulators such as the US FDA, and inspection outcomes can affect exports
  • Product availability: brands and prices vary by state and pharmacy, and prescription medicines should only be used on a doctor's advice

Frequently asked questions

Which is the largest pharmaceutical company in India?

Sun Pharmaceutical Industries is generally described as India's largest pharmaceutical company, including in the company's own materials. Rankings can differ depending on whether they use domestic sales, total revenue or market value, so treat any single ranking as one measure among several.

Why is India called the pharmacy of the world?

The phrase reflects scale and affordability. According to IBEF, India is the largest supplier of generic medicines and provides about 20 per cent of global generic supply by volume, exporting to 191 countries in 2024-25.

What is the difference between an API company and a formulations company?

An API company makes the active ingredient that gives a medicine its effect. A formulations company turns ingredients into finished tablets, capsules, injections or sprays and sells them, often under brand names. Divi's and Laurus are known mainly for APIs and contract work, while companies such as Alkem and Mankind focus on branded formulations. Many large groups, including Aurobindo and Ipca, do both.

Which Indian companies are strongest in biosimilars?

Biocon is the clearest specialist, with ten commercialised biosimilars through Biocon Biologics. Zydus has launched biosimilars including Anyra in 2026, and Aurobindo is building a biosimilars portfolio through its CuraTeQ unit, which won European approvals in 2025.

Are these companies ranked from best to worst?

No. The profiles run in an editorial order chosen for coverage, not as a league table. Companies differ too much in focus, from APIs to biosimilars to branded generics, for a single ranking to be fair.

How can I check a company's latest results myself?

Listed companies publish results and announcements on the BSE and NSE websites and in the investor relations sections of their own websites. Annual reports give the fullest picture of strategy, risks and therapy area performance.

Advertisement
VisitBest Editorial Team

We research public sources, compare practical options, and edit guides for clarity. We update time-sensitive details when reliable information changes and flag claims that need verification.